Navigation Links
New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
Date:5/8/2009

addition, 73 percent and 44 percent reached the ambulatory targets of <130/80 mm Hg and <120/80 mm Hg, respectively.

"The ability of Benicar(R) to bring elderly patients to blood pressure targets is very important, since attaining blood pressure targets can be so challenging in this group," said Dr. Joel M. Neutel, MD, director, Orange County Heart Institute and Research Center. "Although some physicians may be reluctant to use aggressive treatments for fear of an increased risk of adverse events, the findings show hypertension treatment can be accomplished safely and effectively in the elderly."

Benicar was well tolerated by elderly patients, with only nine of the initial 178 patients discontinuing treatment because of treatment emergent adverse events (AEs). In this trial, occurrence of drug-related AEs included: dizziness (3.4 percent), hypotension (2.2 percent), and/or headache (1.1 percent).

High blood pressure can cause permanent changes to blood vessels and the heart that may create serious problems elsewhere in the body.(4) Hypertension is one of the most prevalent conditions in the United States, affecting approximately one in three American adults (about 73 million people age 20 and older) and approximately one billion people worldwide.(5),(6) It is often difficult to control, and of those with high blood pressure, approximately 55 percent do not reach recommended BP levels.(7) The number of people with high blood pressure is expected to reach about 1.6 billion worldwide by 2025.(8)

Patients Older Than 75

A sub analysis of the trial found that 82.5 percent and 67.5 percent of patients over age 75 treated with BENICAR and BENICAR HCT(R) were able to achieve an ambulatory BP target of <135/85 and <130/80 mm Hg, respectively. Adverse events were also found to be similar for patients above and below 75 years of age.

About the
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  TechAtlas Group has announced the release of ... for the Chronic Kidney Disease (CKD) market. This ... drugs and devices currently on the market and ... (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... renal denervation , diabetic nephropathy - antifibrotics ...
(Date:5/17/2013)... MIAMI LAKES, Fla. , May 17, 2013 ... products and delivery technology company that is developing new, patent-pending ... and minerals, announced today that it will hold a business ... on Wednesday, May 22 nd , 2013 at 4:30 PM ... Brian Tuffin will host the call and will ...
(Date:5/17/2013)... , May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... study, JAKARTA , examining the selective ... endpoint in both dose groups. The primary endpoint assessed ... volume. Consistent with data reported in previous trials, the ... vomiting. Full results will be presented at an upcoming ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
(Date:5/20/2013)... May 20, 2013 Widely regarded as ... genital plastic surgery and women’s sexual health, Dr. Goodman ... Board of http://www.labiaplastysurgeon.com , the nationally ranked ... proud to be a member of this informative and ... the appointment. “I’ve already worked with the President ...
(Date:5/20/2013)... May 20, 2013 AURORA, Colo. – ... online accredited university, has developed a Bachelor of ... assess how they feel about continuing their education and ... print out the complimentary worksheet, respond to ten statements ... they rate on a BSN-readiness scale. , New industry ...
(Date:5/20/2013)... Columbus, OH (PRWEB) May 20, 2013 ... an experienced medical device law firm, report that two ... the coming months in state and federal litigations established ... On June 11th, the first C.R. Bard bellwether trial ... Court, Southern District of West Virginia. (In re: ...
(Date:5/20/2013)... Durham, N.C. (PRWEB) May 20, 2013 ... Training Institute (IFPTI), will speak at North Carolina Food ... Food is Good Business: The Need for Partnerships – ... , The two-day conference, scheduled for May 22-23 at ... role partnerships across the food sector have in protecting ...
(Date:5/19/2013)... Houston,TX (PRWEB) May 20, 2013 Due ... companies with online advertising, MileageAds.com has decided to invite ... advertisements through their ad network. , Businesses in ... of success with online marketing, specifically with ad networks. ... advice, information and legal services and are unsure where ...
Breaking Medicine News(10 mins):Health News:Globally Respected Feminine Cosmetic Genital Surgeon Joins Board of Industry Leading Labiaplasty Medical Website 2Health News:Globally Respected Feminine Cosmetic Genital Surgeon Joins Board of Industry Leading Labiaplasty Medical Website 3Health News:American Sentinel University Develops New Worksheet to Help Nurses Determine BSN-Readiness 2Health News:American Sentinel University Develops New Worksheet to Help Nurses Determine BSN-Readiness 3Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 2Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 3Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 4Health News:IFPTI Executive Director to Speak at North Carolina Food Safety and Defense Task Force Annual Conference 2Health News:Mileageads Ad Network Now Invites Bloggers and Business Owners in Mesothelioma Sector to Advertise on Their Ad Network 2
... solutions to tackle obesity, the latest on the Northwick ... sport and the Olympics will be highlighted at ... Pharmacological Society (BPS), Europe,s leading pharmacological research society, is ... attracting experts from across the world. , Running from ...
... Public Relations Worldwide (Ogilvy PR), an integrated global communications ... five-year comprehensive communications support contract with the National Cancer ... will be performed by Ogilvy PR,s Washington, DC-based Social ... consulting subsidiary, Feinstein Kean Healthcare (FKH). , ...
... But American physicians often overlook the illness, delaying diagnosis ... doctors view leprosy as a scourge of Biblical times ... U.S. cases, with more diagnosed each year, experts say. ... remains a largely forgotten illness, U.S. physicians are often ...
... peginterferon in combination with ribavirin for previously untreated children ... , KENILWORTH, N.J., Dec. ... today announced that the U.S. Food and Drug Administration ... and REBETOL(R) (ribavirin, USP) combination therapy for use in ...
... ANN ARBOR, Mich., Dec. 12 Terumo Corporation ... that,they have entered into an agreement to settle ... companies have a number of lawsuits pending,in which ... The litigations all,involve methods and devices used ...
... Dec. 12 Dignitas Personae (The Dignity of ... Doctrine of the Faith (CDF) on ethical issues arising from ... and human procreation in our heavily scientific age, said Cardinal ... of Catholic Bishops. , , ...
Cached Medicine News:Health News:Leading pharmacologists to meet in Brighton 2Health News:National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support 2Health News:Leprosy Lingers in the U.S. 2Health News:Leprosy Lingers in the U.S. 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 2Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 3Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 4
The Urology C-Arm Table features motorized actuation of height, X-Y, lateral roll and Trendelenburg motions of the tabletop, and is fully accessorized for urologic procedures....
... UroVantage from HealthTronics is ... most versatile urology table ... leap forward in design ... urologists by urologists, the ...
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... The Maxxis™ 400 is a bariatric ... safety for individuals in the home care ... 1000 lbs. (or combined weight of 2) ... depending on frame size selected , ...
Medicine Products: